Zwitterionic peptide dendrimer-based nanocarriers with enhanced stability and biocompatibility for cancer therapy
Colloids and Surfaces B: Biointerfaces · 2026-09 · 265 · 115682
DOI: 10.1016/j.colsurfb.2026.115682 ↗Kurz gefasst
Fachartikel in der Zeitschrift Colloids and Surfaces B: Biointerfaces, 2026-09. Verfasst von Yiwen Dong und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China. Hauptthemen laut MEDLINE: Dendrimers, Peptides, Nanoparticles, Antineoplastic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Fujian Provincial Department of Finance, National Natural Science Foundation of China, Science and Technology Planning Project of Fuzhou.
Abstract (Originalsprache)
Autophagy is a cellular self-degradation process that plays a dual role in cancer. Its mild activation can promote tumor survival, while its excessive activation may lead to autophagy-related cell death. Therefore, synergistic treatment of chemotherapeutic agents and autophagy inducers could be a potential strategy to improve therapeutic outcomes. In this study, a zwitterionic peptide dendrimer was designed to conjugate chemotherapeutics, while autophagy inducer STF-62247 was co-loaded into the zwitterionic vehicles to form zwitterionic peptide dendrimers-based nanoparticles (ZPNs). The zwitterionic peptide dendrimer-based vehicles integrate the advantages of peptide dendrimers and zwitterionic surface properties, enabling self-assembly into a stable nanoscale co-delivery system. The physicochemical characteristics of ZPNs, including size, morphology, surface charge, and stability were studied by dynamic light scattering (DLS), transmission electron microscopy (TEM), a hemolysis assay, and protein adsorption assays. The activated autophagy was observed by TEM and Western Blot (WB) tests, which revealed enhanced autophagy in treated tumor cells. In vivo studies in 4T1 tumor-bearing mice were performed to evaluate both antitumor activity and systemic safety, accompanied by histological and hematological analyses. The results showed that ZPNs@STF achieved tumor inhibition comparable to doxorubicin (DOX) while reducing systemic toxicity, suggesting that zwitterionic peptide dendrimers as a promising and safe platform for combination chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
- Fujian Key Laboratory of Drug Target Discovery and Structural and Functional Research, School of Pharmacy, Fujian Medical University, Fuzhou 350122, China.
- Department of Hepatobiliary Surgery, Fuzhou Second Hospital, Fuzhou 350007, China.
- Department of Oral and Maxillofacial Surgery, School and Hospital of Stomatology, Fujian Medical University, Fuzhou 350002, China.
- Fujian Key Laboratory of Drug Target Discovery and Structural and Functional Research, School of Pharmacy, Fujian Medical University, Fuzhou 350122, China. Electronic address: jyzhuang@fjmu.edu.cn.
- Fujian Key Laboratory of Drug Target Discovery and Structural and Functional Research, School of Pharmacy, Fujian Medical University, Fuzhou 350122, China. Electronic address: ningli@fjmu.edu.cn.
Förderung
- Fujian Provincial Department of Finance
- National Natural Science Foundation of China
- Science and Technology Planning Project of Fuzhou
- Fujian Provincial Natural Science Foundation
- Beijing Science and Technology Planning Project
- Fuzhou Science and Technology Bureau
Zitieren
APA
Dong, Y., Wang, Y., Lv, Y., Jia, J., Li, Y., Shen, L., Chen, Y., Niu, G., Zhuang, J., & Li, N. (2026). Zwitterionic peptide dendrimer-based nanocarriers with enhanced stability and biocompatibility for cancer therapy. Colloids and Surfaces B: Biointerfaces, 265, 115682. https://doi.org/10.1016/j.colsurfb.2026.115682
Vancouver
Dong Y, Wang Y, Lv Y, Jia J, Li Y, Shen L, et al. Zwitterionic peptide dendrimer-based nanocarriers with enhanced stability and biocompatibility for cancer therapy. Colloids and Surfaces B: Biointerfaces. 2026;265:115682. doi:10.1016/j.colsurfb.2026.115682
BibTeX
@article{Dong2026,
author = {Dong, Yiwen and Wang, Yuxin and Lv, Yanzhuo and Jia, Jing and Li, Yanda and Shen, Longhua and Chen, Yang and Niu, Gang and Zhuang, Junyang and Li, Ning},
title = {Zwitterionic peptide dendrimer-based nanocarriers with enhanced stability and biocompatibility for cancer therapy},
journal = {Colloids and Surfaces B: Biointerfaces},
year = {2026},
volume = {265},
pages = {115682},
doi = {10.1016/j.colsurfb.2026.115682}
}
EUVIMED